Feed / LH

Labcorp Holdings Inc.

LH

Healthcare · 311.64 +1.5% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

Labcorp Holdings Inc.'s current read is isolated; its market group is not confirming.

The latest filing evidence is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.

What changed
  • Revenue increased 5.8% versus the comparable filing period.
Company+1.5% todayVolume comparison unavailable
Market group0 of 39 activeHealthcare-Defense Mix · unavailable
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
  • LH's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if LH's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Diagnostics & Research

The latest filing evidence is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.

Evidence that supports
  • Revenue increased 5.8% versus the comparable filing period.
  • Operating margin improved 1.0 percentage points.
  • Net income increased 30.5% versus the comparable filing period.
Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • LH's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations602
Usable filing statements93
Verified relationships4
Evidence supporting the case
  • Latest annual revenue changed +7.2% year over year.
  • Operating margin changed +1.6 percentage points in the latest annual period.
Evidence challenging the case
  • Capital investment and capacity has repeated adverse evidence across 4 filings.
Questions before a position
  • P/E is 22% below the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 16% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 11, 2026

311.64
6m+18.5%12m+14.2%24m+39.2%
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$13.1B-6.0%$24.39-0.5%
2022-12-31$11.9B-9.7%$13.97-6.1%
2023-12-31$12.2B+2.5%$4.77-4.4%
2024-12-31$13.0B+7.0%$8.84-3.7%
2025-12-31$14.0B+7.2%$10.46-0.7%

What management says matters

Persistent and emerging business drivers

Capital investment and capacitynegative · 4 filings
The decrease in net cash used for investing activities for the year ended December 31, 2025 as compared to the year ended December 31, 2024, was primarily due to a decrease in business acquisitions and lower capital expenditures, partially offset by the inves…
10-K · Feb 24, 2026
Legal and regulatory exposuremixed · 4 filings
Subject to customary closing conditions and applicable regulatory approvals, the Company expects the acquisition of select assets from Parkview to close in 2026.
10-Q · May 4, 2026
Demand and volumemixed · 3 filings
The decrease was primarily due to growth in demand as the Company leveraged the growth of its revenues and a decrease in costs related to the Spin-off, partially offset by higher personnel costs and the impact from Invitae.
10-K · Feb 24, 2026
Restructuring and cost reductionsnegative · 3 filings
Provision for Income Taxes Three Months Ended March 31, 2026 2025 Provision for income taxes $ 41.7 $ 62.2 Provision for income taxes as a percentage of earnings from operations before income taxes 13.1 % 22.6 % The decrease in the effective tax rate for the…
10-Q · May 4, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 1.9× · EV/sales 2.2×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

311.64+1.5% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for LH. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Latest filing assessment · baseline

Fundamentals strengthened in the latest filing

10-Q filed 2026-05-04 against the comparable filing from 2025-04-29.

constructive
OperationsconstructiveEvidence score +3
liquidityneutralEvidence score 0
valuationmixed

What improved

  • Revenue increased 5.8% versus the comparable filing period.
  • Operating margin improved 1.0 percentage points.
  • Net income increased 30.5% versus the comparable filing period.

What weakened

No thresholded deterioration was identified.

Filing receipts

Price/mix increased by 2.6% due to organic growth of 1.8%, acquisitions, net of divestitures, of 0.6%, and favorable foreign currency translation of 0.2%.

The decrease in cash used for investing activities for the three months ended March 31, 2026, as compared to the corresponding period in 2025, was primarily due to a decrease in purchases of equity affiliate or other investments and lower capital expenditures, partially offset by an increase in business acquisitions.

arch 31, 2026, as compared to the corresponding period in 2025, was primarily due to a decrease in purchases of equity affiliate or other investments and lower capital expenditures, partially offset by an increase in business acquisitions.

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.

Business ecosystem

The relationships behind LH

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depended on by

FTREFortrea Holdings Inc.investeeMay 5, 2026

Prior to the spin-off which was completed on June 30, 2023 (the “Spin” or “the Separation”), Fortrea existed and functioned as part of Labcorp Holdings Inc., which we refer to in this discussion and analysis as “Labcorp” or “Former Parent.” The following disc…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

LH is currently a Follower in the organic co-movement group Healthcare-Defense Mix. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for LH; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.